Company intelligence / Profile preview

Mach One

Irvine, California, United States

Ownership: Private
Development stage: Other

Overview

Mach One Biotech is a clinical-stage biotechnology company focused on the development of next-generation vaccines for infectious diseases, with a primary emphasis on COVID-19. The company's lead candidate, M1-C19, is a recombinant protein-based vaccine designed to provide robust and durable immunity against SARS-CoV-2 and its emerging variants. Leveraging advanced protein engineering and manufacturing techniques, Mach One aims to produce highly stable and scalable vaccine solutions that can be easily distributed globally. The company is currently advancing its lead program through early-stage clinical trials to evaluate safety, tolerability, and immunogenicity in human subjects.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Mach One.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mach One.

Explore the full profile